Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Verge Genomics
Discovers therapeutics for neurodegenerative diseases utilizing human genomic data.
What they do
Verge Genomics uses human genomic data and an all-in-human translation platform to discover therapies for diseases like ALS and Parkinson's. Their technology bypasses traditional animal models by testing compound efficacy directly on patient-derived tissues, streamlining discovery for pharmaceutical partners.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- South San Francisco, USA
- Region
- North America
- Founded
- 2015
- Total funding
- $134M raised
Notable investors: BlackRock, Eli Lilly, Mercer Street, ALS Investment Fund.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA